Diet and Inflammation

Mitigation of inflammation-induced mood dysregulation by long-chain omega-3 fatty acids

Food for mood: relevance of nutritional Omega-3 Fatty acids for depression and anxiety

Empirically derived food-based dietary inflammatory index is associated with increased risk of psychological disorders in women

Association between dietary inflammatory index and psychological profile in adults

Association between the dietary inflammatory index and common mental health disorders profile scores

Association between dietary inflammatory index and psychological profile in adults

Empirically derived food-based dietary inflammatory index is associated with increased risk of psychological disorders in women

Increased Dietary Inflammatory Index is associated with schizophrenia: results of a case-control study from bahrain

Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: a sub-study of a randomised placebo-controlled trial

Dietary fiber and its associations with depression and inflammation

Association of high-fat diet with neuroinflammation, anxiety-like defensive behavioral responses, and altered thermoregulatory responses in male rats (animal study)

Association between dietary patterns and depressive symptoms among middle-aged adults in China in 2016-2017

Mediterranean Diet and low-grade subclinical inflammation: The Moli-sani Study

The inflammatory potential of the diet is associated with depressive symptoms in different subgroups of the general population

Dietary inflammatory index and recurrence of depressive symptoms: results from the Whitehall II Study

Subramaniapillai et. al (2017) reviews the evidence implicating inflammation in various effector systems in mood disorders, explaining the basis for its consideration in the exploration of conceptual models and treatment opportunities. There is an urgent need to identify novel approaches for a disorder that is a serious burden to sufferers and causes illness-associated disability and other transdiagnostic impairments such as anhedonia (inability to feel pleasure in normally pleasurable activities) and cognitive decline. In part driven by metabolic comorbidities, a large proportion of individuals with mood disorders also have an imbalance in the inflammatory milieu. Since efficacy of current treatments are limiting (symptom remission, lack of functional recovery, and disease modification) this article also reviews novel and repurposed agents that are capable of targeting the immune inflammatory system and possibly correcting an abnormal milieu (for example infliximab).

The role of inflammation in depression: from evolutionary imperative to modern treatment target

Clinical evidence for the microbiome in inflammatory diseases

Dietary Inflammatory Index and non-communicable disease risk: A narrative review